PLP1 and myeloid sarcoma: investigated pulmonary delivery of antigen-specific peptide-containing particles for treatment of MS in murine EAE by testing two different sizes of particles with different trafficking properties: 15μm ‘micron-PLP particles’ that accumulated in the lung and 400-500 nm ‘nano-PLP particles’ that accumulated in the liver and spleen following i.v. administration (162).